Modalis Therapeutics (TSE:4883) Other Long-Term Liabilities : 円33.27 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Modalis Therapeutics Other Long-Term Liabilities?

Modalis Therapeutics's other long-term liabilities for the quarter that ended in Mar. 2024 was 円33.27 Mil.

Modalis Therapeutics's quarterly other long-term liabilities declined from Sep. 2023 (円40.01 Mil) to Dec. 2023 (円34.90 Mil) and declined from Dec. 2023 (円34.90 Mil) to Mar. 2024 (円33.27 Mil).

Modalis Therapeutics's annual other long-term liabilities declined from Dec. 2021 (円339.21 Mil) to Dec. 2022 (円46.76 Mil) and declined from Dec. 2022 (円46.76 Mil) to Dec. 2023 (円34.90 Mil).

Modalis Therapeutics Other Long-Term Liabilities Historical Data

The historical data trend for Modalis Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modalis Therapeutics Other Long-Term Liabilities Chart

Modalis Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Modalis Therapeutics Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long-Term Liabilities	Get a 7-Day Free Trial														-	-	-	-	-

Modalis Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Modalis Therapeutics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Modalis Therapeutics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Modalis Therapeutics (TSE:4883) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modalis Therapeutics Corp (TSE:4883) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

16-5 Nihombashi-Kabuto-cho, Chuo-ku, Tokyo, JPN, 103-0026

Website

https://www.modalistx.com

Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.

Modalis Therapeutics (TSE:4883) Headlines

No Headlines